Aytu Biopharma (AYTU) awards 25,000 restricted shares to its CFO
Rhea-AI Filing Summary
AYTU BioPharma’s Chief Financial Officer, Ryan J. Selhorn, received a grant of 25,000 shares of restricted common stock on July 28, 2026. One-third vests on July 28, 2027, with the remaining shares vesting in eight equal quarterly installments beginning October 28, 2027. Following this award, he directly holds 74,743 shares of common stock. The award is a grant/award acquisition rather than a market purchase and was not made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 25,000 shares
Net Buy
1 txn
Insider
Selhorn Ryan J
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 25,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 74,743 shares (Direct)
Footnotes (1)
- F1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.
Key Figures
Restricted stock granted: 25,000 shares
Shares held after transaction: 74,743 shares
Initial vesting date: July 28, 2027
+1 more
4 metrics
Restricted stock granted
25,000 shares
Grant of restricted common stock to CFO Ryan J. Selhorn on July 28, 2026
Shares held after transaction
74,743 shares
Direct AYTU common stock holdings by Ryan J. Selhorn following the grant
Initial vesting date
July 28, 2027
One-third of the restricted stock grant vests on this date
Remaining vesting installments
8 quarterly installments
Balance vests in eight equal quarterly installments beginning October 28, 2027
Key Terms
restricted stock, vesting, quarterly installments
3 terms
restricted stock financial
"Grant of restricted stock, which vest as follows"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
vesting financial
"which vest as follows: 1/3 on July 28, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
quarterly installments financial
"remaining restricted stock vesting in 8 equal quarterly installments"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did AYTU’s CFO report in this Form 4?
AYTU’s Chief Financial Officer, Ryan J. Selhorn, reported receiving a grant of 25,000 shares of restricted common stock. The grant was awarded on July 28, 2026, as an equity award rather than a market purchase and will vest over time based on a defined schedule.
Was the AYTU CFO’s restricted stock grant made under a Rule 10b5-1 plan?
No. The filing indicates the grant to AYTU’s CFO was not made pursuant to a Rule 10b5-1 trading plan. It is reported simply as a grant or award acquisition of restricted stock, rather than a transaction executed under a pre-arranged trading program.
What type of transaction does AYTU’s latest Form 4 for the CFO report?
The Form 4 for AYTU’s CFO reports a grant/award acquisition of restricted stock, coded as “A” for acquisition. It covers 25,000 shares of common stock awarded at a stated price of $0.00 per share, reflecting a compensatory equity grant instead of an open-market trade.